Crinetics Pharmaceuticals (CRNX) Return on Sales (2017 - 2026)

Crinetics Pharmaceuticals' Return on Sales history runs 10 years deep, the most recent figure standing at 0.12% for Q1 2026.

• In Q1 2026, Return on Sales rose 256.0% year-over-year to 0.12%; the TTM figure through Mar 2026 stood at 0.27% (up 404.0% YoY), while the FY2025 annual figure was 0.6%, up 226.0% from the prior year.
• Return on Sales was 0.12% for Q1 2026 at Crinetics Pharmaceuticals, up from 0.2% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.11% in Q1 2022 to a low of 9.1% in Q3 2025.
• Historically, Return on Sales has averaged 1.59% across 5 years, with a median of 0.96% in 2022.
• The sharpest annual moves came in 2022 and 2025: Return on Sales slumped 1479 bps in 2022, then surged 267 bps in 2025.
• A 5-year view of Return on Sales shows it stood at 0.64% in 2022, then grew by 19 bps to 0.52% in 2023, then tumbled by 450 bps to 2.87% in 2024, then surged by 93 bps to 0.2% in 2025, then jumped by 40 bps to 0.12% in 2026.
• The last three Return on Sales figures came in at 0.12% (Q1 2026), 0.2% (Q4 2025), and 9.1% (Q3 2025), per Business Quant data.